IDEAYA Biosciences (IDYA) Common Equity (2018 - 2026)

IDEAYA Biosciences (IDYA) has 9 years of Common Equity data on file, last reported at $937.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 8.48% year-over-year to $937.3 million; the trailing twelve-month figure through Mar 2026 stood at $937.3 million (down 8.48% YoY), and the FY2025 full-year result was $1.0 billion, down 3.42% from the prior year.
• Common Equity declined to $937.3 million in Q1 2026, from $1.0 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.2 billion in Q3 2024 to a low of $269.3 million in Q2 2022.
• A 5-year average of $728.4 million and a median of $931.7 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 180.19% in 2024 and declined 8.48% in 2026, its largest moves.
• Tracing IDYA's Common Equity over 5 years: stood at $349.5 million in 2022, then jumped by 77.73% to $621.1 million in 2023, then jumped by 70.53% to $1.1 billion in 2024, then fell by 3.42% to $1.0 billion in 2025, then declined by 8.37% to $937.3 million in 2026.
• Business Quant data shows IDYA's Common Equity at $937.3 million in Q1 2026, $1.0 billion in Q4 2025, and $1.1 billion in Q3 2025.